SCHEMBL30584792

SCHEMBL30584792

COc1ccc(-c2noc(C3CN(C(=O)N4CCC(C)CC4)C3)n2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 3/20 0.66
▸ ALDH1A1 P00352 5/20 0.62
▸ SMN1; SMN2 Q16637 3/20 0.62
▸ MAPT P10636 2/20 0.62
▸ MEN1 O00255 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ HPGD P15428 2/20 0.60
▸ HTT P42858 3/20 0.59
▸ POLB P06746 2/20 0.59
▸ GAA P10253 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2D6 P10635 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ LMNA P02545 3/20 0.58
▸ TSHR P16473 2/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30584774 0.82 MAPT (0.67) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL25172097 0.81 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL25401566 0.79 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5635354 0.78 MEN1 (0.60) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL193795 0.78 MEN1 (0.82) GRM5ALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL4415594 0.77 HTT (0.57) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL193587 0.77 ALDH1A1 (0.70) GRM5ALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL20116343 0.75 TSHR (0.65) GRM5MEN1KMT2AHPGDHTT
SCHEMBL30584793 0.74 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL20676389 0.73 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 GRM5 4334/4885ALDH1A1 4471/4885SMN1; SMN2 3115/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 GRM5 4334/4885ALDH1A1 4471/4885SMN1; SMN2 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback